Emergency medicine Australasia : EMA
-
Wong briefly summarises COVID pharmaceutical therapies that are currently in trial, and importantly have received media attention.
Highlighting that off-label use of these drugs may be important causes of future toxicological presentations to emergency departments, especially for those widely used in the community for other indications (eg. Plaquenil, Kaletra, colchicine...).
Briefly discussed are:
- Chloroquine/hydroxychloroquine
- Azithromycin
- Kaletra (Lopinavir/ritonavir)
- Colchicine
- Ivermectin
- Tocilizumab
- Thaildomide
- Remdesivir
-
Emerg Med Australas · Aug 2020
Informing Emergency Care for all patients: The Registry for Emergency Care (REC) Project Protocol.
In Australia, the current ED burden related to COVID-19 is from 'suspected' rather than 'confirmed' cases. The initial aim of the Registry for Emergency Care (REC) Project is to determine the impact of isolation processes on the emergency care of all patients. ⋯ The REC Project will support ED clinicians in the emergency care of all patients.